The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Interim analysis of the ELM-2 study: odronextamab in patients with R/R follicular lymphoma
Jose Villasboas, MD, Mayo Clinic, Rochester, MN, discusses the results of a pre-specified interim analysis of the Phase II ELM-2 trial (NCT03888105), which is evaluating the safety and efficacy of odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Dr Villasboas highlights the inclusion criteria for this trial and gives an overview of the patients enrolled in this study. The results of this analysis continue to demonstrate deep and durable responses with odronextamab in this heavily pretreated patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
